Department of Surgery, Boston Medical Center, Boston University School of Medical, Boston, Massachusetts. Electronic address: https://twitter.com/MPapageorge_MD.
Department of Surgery, Boston Medical Center, Boston University School of Medical, Boston, Massachusetts.
J Surg Res. 2023 Nov;291:282-288. doi: 10.1016/j.jss.2023.06.017. Epub 2023 Jul 21.
Patients with pancreatic cancer can present with a variety of insidious abdominal symptoms, complicating initial diagnosis. Early symptoms of pancreatic cancer often mirror those associated with gallstone disease, which has been demonstrated to be a risk factor for this malignancy. This study aims to compare the incidence of gallstone disease in the year before diagnosis of pancreatic ductal adenocarcinoma (PDAC) as compared to the general population, and evaluate the association of gallstone disease with stage at diagnosis and surgical intervention.
Patients with PDAC were identified from SEER-Medicare (2008-2015). The incidence of gallstone disease (defined as cholelithiasis, cholecystitis and/or cholecystectomy) in the 1 year before cancer diagnosis was compared to the annual incidence in an age-matched, sex-matched, and race-matched noncancer Medicare cohort.
Among 14,654 patients with PDAC, 4.4% had gallstone disease in the year before cancer diagnosis. Among the noncancer controls (n = 14,654), 1.9% had gallstone disease. Both cohorts had similar age, sex and race distributions. PDAC patients with gallstone disease were diagnosed at an earlier stage (stage 0/I-II, 45.8% versus 38.1%, P < 0.0001) and a higher proportion underwent resection (22.7% versus 17.4%, P = 0.0004) compared to patients without gallstone disease.
In the year before PDAC diagnosis, patients present with gallstone disease more often than the general population. Improving follow-up care and differential diagnosis strategies may help combat the high mortality rate in PDAC by providing an opportunity for earlier stage of diagnosis and earlier intervention.
患有胰腺癌的患者可能会出现多种隐匿性腹部症状,从而使初始诊断变得复杂。胰腺癌的早期症状常常与胆石病的症状相似,胆石病已被证明是这种恶性肿瘤的一个危险因素。本研究旨在比较在诊断为胰腺导管腺癌 (PDAC) 前一年患有胆石病的发病率与普通人群相比,并评估胆石病与诊断时的分期和手术干预的相关性。
从 SEER-Medicare(2008-2015 年)中确定 PDAC 患者。在癌症诊断前 1 年胆石病(定义为胆石症、胆囊炎和/或胆囊切除术)的发生率与年龄、性别和种族相匹配的非癌症医疗保险队列的年发病率进行比较。
在 14654 例 PDAC 患者中,4.4%的患者在癌症诊断前 1 年患有胆石病。在非癌症对照组中(n=14654),有 1.9%的患者患有胆石病。两个队列的年龄、性别和种族分布相似。患有胆石病的 PDAC 患者的诊断分期更早(0/I-II 期,45.8%比 38.1%,P<0.0001),并且更多的患者接受了切除术(22.7%比 17.4%,P=0.0004)。
在 PDAC 诊断前 1 年,患有胆石病的患者比普通人群更常见。改善后续护理和鉴别诊断策略可能有助于通过提供更早诊断和更早干预的机会,降低 PDAC 的高死亡率。